| Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase K Babaoglu, A Simeonov, JJ Irwin, ME Nelson, B Feng, CJ Thomas, ... Journal of medicinal chemistry 51 (8), 2502-2511, 2008 | 188 | 2008 |
| The Hippo Pathway and YAP/TAZ–TEAD Protein–Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment: Miniperspective M Santucci, T Vignudelli, S Ferrari, M Mor, L Scalvini, ML Bolognesi, ... Journal of medicinal chemistry 58 (12), 4857-4873, 2015 | 168 | 2015 |
| Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development A Cavazzuti, G Paglietti, WN Hunter, F Gamarro, S Piras, M Loriga, ... Proceedings of the National Academy of Sciences 105 (5), 1448, 2008 | 159 | 2008 |
| Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity N Realini, C Solorzano, C Pagliuca, D Pizzirani, A Armirotti, R Luciani, ... Scientific reports 3 (1), 1035, 2013 | 154 | 2013 |
| 2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 J Neres, RC Hartkoorn, LR Chiarelli, R Gadupudi, MR Pasca, G Mori, ... ACS chemical biology 10 (3), 705-714, 2015 | 123 | 2015 |
| Thymidylate synthase structure, function and implication in drug discovery MP Costi, S Ferrari, A Venturelli, S Calo, D Tondi, D Barlocco Current medicinal chemistry 12 (19), 2241-2258, 2005 | 123 | 2005 |
| Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. CMP Cardinale D, Guaitoli G, Tondi D, Luciani R Proceeding National Academy of Science 108, 16133, 2011 | 103* | 2011 |
| Virtual Screening Identification of Nonfolate Compounds, Including a CNS Drug, as Antiparasitic Agents Inhibiting Pteridine Reductase S Ferrari, F Morandi, D Motiejunas, E Nerini, S Henrich, R Luciani, ... Journal of medicinal chemistry, 2011 | 88 | 2011 |
| Structure-based discovery and in-parallel optimization of novelcompetitive inhibitors of thymidylate synthase D Tondi, U Slomczynska, MP Costi, DM Watterson, S Ghelli, BK Shoichet Chemistry & biology 6 (5), 319-331, 1999 | 88 | 1999 |
| Update on antifolate drugs targets MP Costi, S Ferrari Current drug targets 2 (2), 135-166, 2001 | 81 | 2001 |
| Structure-based optimization of a non-β-lactam lead results in inhibitors that do not up-regulate β-lactamase expression in cell culture D Tondi, F Morandi, R Bonnet, MP Costi, BK Shoichet Journal of the American Chemical Society 127 (13), 4632-4639, 2005 | 77 | 2005 |
| Structure-based design and in-parallel synthesis of inhibitors of AmpC β-lactamase D Tondi, RA Powers, E Caselli, MC Negri, J Blázquez, MP Costi, ... Chemistry & Biology 8 (6), 593-610, 2001 | 74 | 2001 |
| Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance L Taddia, D D’Arca, S Ferrari, C Marraccini, L Severi, G Ponterini, ... Drug Resistance Updates 23, 20-54, 2015 | 72 | 2015 |
| Structure-Based Design of Inhibitors Specific for Bacterial Thymidylate Synthase, TJ Stout, D Tondi, M Rinaldi, D Barlocco, P Pecorari, DV Santi, ID Kuntz, ... Biochemistry 38 (5), 1607-1617, 1999 | 64 | 1999 |
| Combination of Suboptimal Doses of Inhibitors Targeting Different Domains of LtrMDR1 Efficiently Overcomes Resistance of Leishmania spp. to Miltefosine by … JM Pérez-Victoria, F Cortés-Selva, A Parodi-Talice, BI Bavchvarov, ... Antimicrobial agents and chemotherapy 50 (9), 3102-3110, 2006 | 63 | 2006 |
| Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs D Garg, S Henrich, OMH Salo-Ahen, H Myllykallio, MP Costi, RC Wade Journal of medicinal chemistry 53 (18), 6539-6549, 2010 | 59 | 2010 |
| Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and-resistant human ovarian cancer cells G Marverti, A Ligabue, P Lombardi, S Ferrari, MG Monti, C Frassineti, ... International Journal of Oncology 43 (4), 1269-1280, 2013 | 55 | 2013 |
| Novel 3‐benzoyl‐2‐piperazinylquinoxaline derivatives as potential antitumor agents S Piras, M Loriga, A Carta, G Paglietti, M Paola Costi, S Ferrari Journal of heterocyclic chemistry 43 (3), 541-548, 2006 | 55 | 2006 |
| Current and future chemotherapy for Chagas disease L Gaspar, C B Moraes, L H Freitas-Junior, S Ferrari, L Costantino, ... Current medicinal chemistry 22 (37), 4293-4312, 2015 | 54 | 2015 |
| Homodimeric enzymes as drug targets D Cardinale, OMH Salo-Ahen, S Ferrari, G Ponterini, G Cruciani, ... Current medicinal chemistry 17 (9), 826-846, 2010 | 54 | 2010 |
